At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRNA Moderna, Inc.
Post-Mkt 08-12 19:20:04 EDT
63.67
+3.10
+5.12%
盘后63.70
+0.03+0.05%
19:14 EDT
High64.26Low59.29Vol6.57M
Open60.58D1 Closing60.57Amplitude8.21%
Mkt Cap25.42BTradable Cap23.43BTotal Shares399.24M
T/O414.52MT/O Rate1.79%Tradable Shares368.05M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Moderna Inc. Stock Rises 5.1%, Outperforms Peers
Dow Jones  ·  04:34
Moderna Inc. Stock Rises 5.1%, Outperforms Peers
Stock Track | Moderna Soars Over 5% Intraday on First mRNA Flu Vaccine FDA Approval and Q2 Earnings Beat
Stock Track  ·  00:00
Stock Track | Moderna Soars Over 5% Intraday on First mRNA Flu Vaccine FDA Approval and Q2 Earnings Beat
Movement Alert｜Moderna, Inc. Rises 5.17% in Regular Trading, First mRNA Flu Vaccine FDA Approval Combined with Q2 Earnings Beat
Market Focus  ·  08-12 23:57
Movement Alert｜Moderna, Inc. Rises 5.17% in Regular Trading, First mRNA Flu Vaccine FDA Approval Combined with Q2 Earnings Beat
Stock Track | Moderna Soars 5% in Pre-Market as FDA Approval of First mRNA Flu Vaccine Continues to Drive Gains
Stock Track  ·  08-10 16:54
Stock Track | Moderna Soars 5% in Pre-Market as FDA Approval of First mRNA Flu Vaccine Continues to Drive Gains
Movement Alert｜Moderna, Inc. Rises 5.15% in Pre-Market Trading, First mRNA Flu Vaccine FDA Approval Continues to Boost Shares
Market Focus  ·  08-10 16:53
Movement Alert｜Moderna, Inc. Rises 5.15% in Pre-Market Trading, First mRNA Flu Vaccine FDA Approval Continues to Boost Shares
Moderna Inc. Stock Climbs 9.9%, Outperforms Peers
Dow Jones  ·  08-08
Moderna Inc. Stock Climbs 9.9%, Outperforms Peers
Moderna CEO Stephane Bancel Disposes of 499,246 Shares for $9.56 Million
Reuters  ·  08-08
Moderna CEO Stephane Bancel Disposes of 499,246 Shares for $9.56 Million
Stock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval
Stock Track  ·  08-07
Stock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval
Movement Alert｜Moderna, Inc. Rises 5.31% in Regular Trading, First mRNA Flu Vaccine Wins FDA Approval
Market Focus  ·  08-07
Movement Alert｜Moderna, Inc. Rises 5.31% in Regular Trading, First mRNA Flu Vaccine Wins FDA Approval
Soligenix Q2 Net Loss Narrows as R&D Expenses Fall
Reuters  ·  08-07
Soligenix Q2 Net Loss Narrows as R&D Expenses Fall
Moderna Inc. Stock Sheds 4.3%, Underperforms Peers
Dow Jones  ·  08-07
Moderna Inc. Stock Sheds 4.3%, Underperforms Peers
Arcturus Q2 Revenue Falls Sharply on CSL Seqirus Deal End
Reuters  ·  08-07
Arcturus Q2 Revenue Falls Sharply on CSL Seqirus Deal End
U.S. Stocks on the MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International
Reuters  ·  08-07
U.S. Stocks on the MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International
Moderna Stock Slips Despite FDA Approval for New Flu Shot mFlusiva
TIPRANKS  ·  08-06
Moderna Stock Slips Despite FDA Approval for New Flu Shot mFlusiva
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), Exelixis (EXEL) and Moderna (MRNA)
TIPRANKS  ·  08-06
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), Exelixis (EXEL) and Moderna (MRNA)
Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future
Dow Jones  ·  08-06
Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future
Pre-Market Outlook: US Index Futures Mixed; Memory Chip Stocks Slide on SanDisk and Western Digital Guidance Miss
Stock News  ·  08-06
Pre-Market Outlook: US Index Futures Mixed; Memory Chip Stocks Slide on SanDisk and Western Digital Guidance Miss
Novavax Lifts Annual Revenue Forecast as Licensing Bets Offset Weak Vaccine Demand
Reuters  ·  08-06
Novavax Lifts Annual Revenue Forecast as Licensing Bets Offset Weak Vaccine Demand
U.S. Stocks on the MOVE-Cheniere Energy, TPG, Constellation Energy
Reuters  ·  08-06
U.S. Stocks on the MOVE-Cheniere Energy, TPG, Constellation Energy
Roivant Q1 FY27 Net Loss Widens to $290.61 Million; Revenue Slips to $1.44 Million
Reuters  ·  08-06
Roivant Q1 FY27 Net Loss Widens to $290.61 Million; Revenue Slips to $1.44 Million

Introduction

Company Name.
Moderna, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Issue price:
--